Eupraxia OTC Stock Financials

EPRXF -  USA Stock  

USD 2.30  0.00  0.00%

Understanding current and past Eupraxia Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Eupraxia Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Eupraxia Pharmaceuticals' assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Eupraxia Pharmaceuticals' financials over time to get the whole picture.
.
We urge to utilize analysis of Eupraxia Pharmaceuticals fundamentals to see if markets are presently mispricing the company. We have analyzed and interpolated nineteen available fundamental indicators for Eupraxia Pharmaceuticals, which can be compared to its rivals. Use Eupraxia Pharmaceuticals ebitda, debt to equity, as well as the relationship between the Debt to Equity and market capitalization to make sure your decision on pricing Eupraxia Pharmaceuticals is adequate. Please also check Eupraxia Pharmaceuticals cash per share to verify the company can sustain itself down the road. Use Eupraxia Pharmaceuticals to protect your portfolios against small market fluctuations. The stock experiences a normal downward fluctuation but is a risky buy. Check odds of Eupraxia Pharmaceuticals to be traded at $2.28 in 90 days.

Eupraxia Fundamentals 

 
Refresh
With this module, you can analyze Eupraxia financials for your investing period. You should be able to track the changes in Eupraxia Pharmaceuticals individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Chance Of Financial Distress
Over 64
Eupraxia Pharmaceuticals has more than 64 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Eupraxia Pharmaceuticals otc stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Eupraxia Pharmaceuticals' official financial statements usually reflect Eupraxia Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Eupraxia Pharmaceuticals. For example, before you start analyzing numbers published by Eupraxia accountants, it's critical to develop an understanding of what Eupraxia Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Eupraxia Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eupraxia Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Eupraxia Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eupraxia Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Eupraxia Pharmaceuticals' management to manipulate its earnings.

Eupraxia Pharmaceuticals Company Summary

Eupraxia Pharmaceuticals competes with Csl, Regeneron Pharmaceuticals, Moderna, and Vertex Pharmaceutic. Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The companys lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
InstrumentUSA OTC Stock View All
ExchangeOTC Exchange
Business Address2067 Cadboro Bay
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.eupraxiapharma.com
Phone250 590 3968
CurrencyUSD - US Dollar
You should never invest in Eupraxia Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Eupraxia OTC Stock, because this is throwing your money away. Analyzing the key information contained in Eupraxia Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Eupraxia Pharmaceuticals Key Financial Ratios

Generally speaking, Eupraxia Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Eupraxia Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Eupraxia Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Eupraxia Pharmaceuticals reports annually and quarterly.

Eupraxia Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Eupraxia Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Eupraxia Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eupraxia Pharmaceuticals competition to find correlations between indicators driving Eupraxia Pharmaceuticals's intrinsic value. More Info.
Eupraxia Pharmaceuticals is one of the top stocks in shares owned by insiders category among related companies. It is rated # 5 in earnings per share category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Eupraxia Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Eupraxia Pharmaceuticals' OTC Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Eupraxia Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Eupraxia Pharmaceuticals Systematic Risk

Eupraxia Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Eupraxia Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of ninety-three. The Beta measures systematic risk based on how returns on Eupraxia Pharmaceuticals correlated with the market. If Beta is less than 0 Eupraxia Pharmaceuticals generally moves in the opposite direction as compared to the market. If Eupraxia Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Eupraxia Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Eupraxia Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Eupraxia Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Eupraxia Pharmaceuticals Financials

What exactly are Eupraxia Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Eupraxia Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Eupraxia Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Eupraxia Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Eupraxia Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eupraxia Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Eupraxia Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Eupraxia grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Eupraxia Pharmaceuticals January 26, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Eupraxia Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Eupraxia Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Eupraxia Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Eupraxia OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Eupraxia Pharmaceuticals's daily price indicators and compare them against related drivers.
Information Ratio(0.09)
Maximum Drawdown22.58
Continue to Investing Opportunities. Note that the Eupraxia Pharmaceuticals information on this page should be used as a complementary analysis to other Eupraxia Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Eupraxia OTC Stock analysis

When running Eupraxia Pharmaceuticals price analysis, check to measure Eupraxia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eupraxia Pharmaceuticals is operating at the current time. Most of Eupraxia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eupraxia Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Eupraxia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eupraxia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Is Eupraxia Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eupraxia Pharmaceuticals. If investors know Eupraxia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eupraxia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eupraxia Pharmaceuticals is measured differently than its book value, which is the value of Eupraxia that is recorded on the company's balance sheet. Investors also form their own opinion of Eupraxia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eupraxia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eupraxia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eupraxia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eupraxia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Eupraxia Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eupraxia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.